Qiagen has collaborated with Denovo Biopharma for the development of a companion diagnostic (CDx) test to identify Diffuse Large B-Cell Lymphoma (DLBCL) patients expressing a biomarker.

Under the terms of the deal, Qiagen will develop a new test that would be capable of detecting the Denovo Genomic Marker 1 (DGM1) in DLBCL patients.

Discovered by Denovo, DGM1 predicts the responsiveness to the company’s investigational cancer drug DB102 to treat DLBCL.

DB102, which is also known as enzastaurin, is a small molecule inhibitor of the PKC-beta protein, which has been connected to DLBCL cases.

Qiagen oncology and precision diagnostics head and vice-president Jonathan Arnold said: “We are proud to be at the cutting edge of precision medicine, a quantum leap from traditional one-drug-fits all medicine.

“Our molecular testing expertise will help Denovo to develop the use of the DGM1 marker with the DB102 drug for patients with DLBCL.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company will develop a real-time qualitative polymerase chain reaction (PCR) CDx for use on its Rotor-Gene Q MDx instrument.

It will also seek the US Food and Drug Administration’s (FDA) premarket approval (PMA) for the new test.

The companies aim to obtain the PMA along with Denovo receiving approval for its new drug application (NDA) for DB102.

At present, the drug and biomarker are being evaluated in the Phase III ENGINE trial on high-risk DLBCL patients who are newly diagnosed.

Denovo chief technology officer Xiao-Xiong Lu said: “As our ENGINE trial nears completion, we are pleased to be working with Qiagen on commercial development of our DB102 programme to enable patients and physicians to potentially benefit from DB102 treatment.

“As a pioneer in precision medicine, Qiagen brings extensive experience in CDx, including ten FDA-approved tests.”

Recently, Qiagen received CE mark for its QuantiFeron SARS-CoV-2 assay, which measures T-cell responses to Covid-19.